Lyon, France
Joined February 2012
- Tweets4.6K
- Following758
- Followers374
- Likes414
Thomas Pierret 🫁 retweeted
#ESMO26 Dr. Jarushka Naidoo @DrJNaidoo with a fantastic discussion on de-escalation trials in oncology. A call out on why de-escalation studies are important and their limitations. And for MOIO in particular - lessons on trial design, non-inferiority, and pragmatism. A must-listen to all involved in trial design. #ESMOAmbassadors
Thomas Pierret 🫁 retweeted
#ESMO26 One of my favorite discussant. Dr @JordiRemon discusses early stage immunotherapy abstracts. Many options in the neoadjuvant and perioperative space, summarized beautifully. What is the value of adjuvant immunotherapy? Is receipt of adjuvant therapy a surrogate for fitness? #ESMOAmbassadors
Thomas Pierret 🫁 retweeted
#ESMO26 Does Tarlatamab provide long term benefit to responding patients?
✅The answer is Yes!
➡️Extended F-UP of the Dellphi-304 trial shows that after 22m of F-UP Landmark 2-year OS was 30% vs 15% and sustained disease control in 24% of patients at > 52 weeks
❓We need to investigate the characteristics of those patients to understand how we can improve the outcomes of the 70% of patients who do not make it to two years
@myESMO
#ESMOAmbassadors
Thomas Pierret 🫁 retweeted
📢 #ESMO26 concomitant paper: Extended follow-up of #tarlatamab in patients with small-cell lung cancer after platinum-based chemo in the phase 3 DeLLphi-304 study.
🔗shorturl.at/QFAwC
@JulienMazieres @pedrofrocha @UniklinikEssen @medizinischefakultaet @g_mountzios
Thomas Pierret 🫁 retweeted
🔥DeLLphi-304: Extended follow-up of tarlatamab vs chemo in 2L SCLC
🆙 @Annals_Oncology #ESMO26
🎙 @charlesrudin
🎯Durable OS Benefit at 23-Mo Median Follow-Up
🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24%
🎯Grade≥3 TRAEs 28% vs 63%
☑️NCT05740566
@OncoAlert @Larvol @myESMO @IASLC
annalsofoncology.org/article…
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets
🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial
🎙️ @charlesrudin
🔢3808O
🎯Durable OS Benefit at 23-Mo Median Follow-Up
🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24%
🎯Grade≥3 TRAEs 28% vs 63%
☑️NCT05740566
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
Thomas Pierret 🫁 retweeted
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets
🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial
🎙️ @charlesrudin
🔢3808O
🎯Durable OS Benefit at 23-Mo Median Follow-Up
🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24%
🎯Grade≥3 TRAEs 28% vs 63%
☑️NCT05740566
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets
🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial
🎙️ @charlesrudin
🔢3808O
🎯Durable OS Benefit at 23-Mo Median Follow-Up
🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24%
🎯Grade≥3 TRAEs 28% vs 63%
☑️NCT05740566
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
Thomas Pierret 🫁 retweeted
#ESMO26 Dr. @RobertoFerrara_ explains next-generation immune toxicities seen with next-generation immunotherapies. Rational design of SCORPION vs CRAB antibodies is a good example of intentional design to address toxicities. Very helpful overview. #ESMOAmbassadors
Thomas Pierret 🫁 retweeted
Savo + Osi >>> Osi
In 1L stage IV, EGFRmut: Better PFS and remarkable 44.5 OS for a poor prognosis population, with the cost of more MET-related side effects.
High attrition to find MET-IHC3+. Wondering how this data compares to this subset of patients in the MARIPOSA trial. #ESMO26 #LCSM
Thomas Pierret 🫁 retweeted
ESMO 2026 | A cautionary tale for immunotherapy de-escalation!
MOIO Trial (LBA10) – Phase III non-inferiority trial testing 3-monthly immunotherapy vs standard dosing in responding patients with advanced/metastatic cancer.
📊 Key results (N=308):
• Median PFS: 21.9 vs 25 months (reduced vs standard; HR 1.35)
• Risk of death: HR 2.0 (95% CI 1.1–3.9; p=0.0143) ⚠️
• PFS HR in urothelial cancer: 2.9
• Grade 3–4 immune-related AEs: 9.5% vs 10.5%
❌ Non-inferiority NOT demonstrated.
❌ No meaningful safety advantage.
⚠️ Signal of inferior survival with reduced-frequency IO.
💡 Take-home: Less frequent immunotherapy is not necessarily equally effective!
Important: These are interim results with relatively small numbers and heterogeneous tumour types.
#ESMO26 #MOIO #Immunotherapy #Oncology @OncoAlert @myESMO
Thomas Pierret 🫁 retweeted
Pembro monotherapy still has a role in selected pts (borderline ECOG PS or where a pt does not want to do chemo) but the control arm did not underperform. The final median PFS for Pembro mono in KN024 was only 3 weeks less than the control arm performance in PERSEE was it not?
Thomas Pierret 🫁 retweeted
Brilliant discussion from Dr. @BenjaminBesseMD at #ESMO26 on the Krascendo 1 study of divarasib vs sotorasib/adagrasib. Rightly points out lack of crossover in a study with a PFS endpoint as unjust. Excellent points all around. #ESMOAmbassadors
Thomas Pierret 🫁 retweeted
No information by molecular subtypes (eg KRAS mut) or elderly patients where combination may be not necessary or even detrimental because of side effects.
Thomas Pierret 🫁 retweeted
Impressive results Academic III PERSEE #ESMO26 @Annals_Oncology First positive random trial adding chemo to pembro in PD-L1 ≥50% NSCLC:
🔹 PFS: 16.1 vs 6.9 mo HR 0.56
🔹 OS: 50.2 vs 29.9 mo HR 0.77, NS
🔹 G≥3 TRAEs: 54% vs 19%
Outstanding discussion Prof. Levy
@benlevylungdoc.
Thomas Pierret 🫁 retweeted
‼️ In first line treatment of advanced PD-L1 ≥50% NSCLC, PERSEE demonstrates a significant improvement of PFS with pembro-CT compared to pembro monotherapy regardless of PDL1 level of (over)expression. Practise changing trial. @myESMO @OncoAlert #ESMO26 👏👏👏 @decroisette
Thomas Pierret 🫁 retweeted
Randomised phase 3 Persée study presented at #ESMO26 this morning
➡️ chemotherapy and Pembrolizumab improved OS when compared with Pembro alone in patients with local advanced NSCLC with PD-L1 ≥50%
Thomas Pierret 🫁 retweeted
Off the rousing #ESMO26 oral presentation from Dr. @decroisette, the phase III PERSEE trial with simultaneous publication @Annals_Oncology. Combination of chemotherapy + pembrolizumab superior to pembro in PDL1 high NSCLC: PFS 16.1 vs 6.9m, HR 0.56!
annalsofoncology.org/article…
Thomas Pierret 🫁 retweeted
🆙#ESMO26 Proffered Paper I: #LCSM Mets
🔥OptiTROP-Lung04: Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) Versus Platinum-Based Chemotherapy in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) After Progression on EGFR-TKI: Phase III Study
🎙️Dr. Wenfeng Fang
🔢LBA67
🎯Sustained OS Benefit at 32.3-Mo Follow-Up
🎯Median OS 25.9 vs 17.4mo (HR 0.69; n=376)
🎯24-Mo OS 54.1% vs 37.2%
☑️NCT05870319
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
🆙 #ESMO26 Proffered Paper I: #LCSM Mets
🔥OptiTROP-Lung04: Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) Versus Platinum-Based Chemotherapy in EGFR-Mutated NSCLC After Progression on EGFR-TKI
🎙️Dr. Li Zhang
🔢LBA67
☑️NCT05870319
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
Thomas Pierret 🫁 retweeted
#ESMO26 | SAFFRON | Presidential Session-2
In EGFR-mutant, MET-overexpressed/amplified advanced NSCLC after osimertinib:
Osimertinib + savolitinib vs platinum-pemetrexed:
🔹 PFS: 7.6 vs 5.4 mo (HR 0.55)
🔹 OS: 17.8 vs 12.9 mo(HR 0.68)
Thomas Pierret 🫁 retweeted
#ESMO26 | Presidential Session 2 – KRASCENDO-1
Divarasib vs sotorasib/adagrasib in previously treated KRAS G12C-mutant aNSCLC
- PFS: 9.8 vs 5.7 mo
- OS: 17.7 vs 12.0 mo
- ORR: 58.4% vs 32.3%
- G 3–4 TRAEs: 43.1% vs 51.5%
🔹️Control arm: 156 patients sotorasib and 15 adagrasib
